Avid Bioservices, Inc. (CDMO) News

Avid Bioservices, Inc. (CDMO): $17.11

0.92 (+5.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CDMO News Items

CDMO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CDMO News From Around the Web

Below are the latest news stories about AVID BIOSERVICES INC that investors may wish to consider to help them evaluate CDMO as an investment opportunity.

Avid Bioservices, Inc. (NASDAQ:CDMO) Q2 2023 Earnings Call Transcript

Avid Bioservices, Inc. (NASDAQ:CDMO) Q2 2023 Earnings Call Transcript December 6, 2022 Operator: Good day, ladies and gentlemen. And welcome to the Avid Bioservices Second Quarter Fiscal 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that […]

Yahoo | December 9, 2022

Avid Bioservices Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

Avid Bioservices ( NASDAQ:CDMO ) Second Quarter 2023 Results Key Financial Results Revenue: US$34.8m (up 33% from 2Q...

Yahoo | December 9, 2022

Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 0% and 12.12%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | December 6, 2022

Edited Transcript of CDMO.OQ earnings conference call or presentation 6-Dec-22 9:30pm GMT

Q2 2023 Avid Bioservices Inc Earnings Call

Yahoo | December 6, 2022

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments

-- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year -- -- Mammalian Cell Facilities and Cell and Gene Therapy Facility Expansions Continue on Schedule -- -- Revenue Guidance for Fiscal 2023 Increased to $145 to $150 Million -- TUSTIN, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturin

Yahoo | December 6, 2022

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022

TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2023 on December 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members

Yahoo | November 29, 2022

Avid Bioservices (NASDAQ:CDMO) jumps 12% this week, though earnings growth is still tracking behind five-year shareholder returns

Avid Bioservices, Inc. ( NASDAQ:CDMO ) shareholders might be concerned after seeing the share price drop 23% in the...

Yahoo | November 17, 2022

Avid Bioservices Appoints Oksana Lukash as Vice President, People

TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial org

Yahoo | November 16, 2022

Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference

TUSTIN, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Credit Suisse 31st Annual Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will deli

Yahoo | November 2, 2022

Does Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?

The consensus price target hints at a 60.5% upside potential for Avid Bioservices (CDMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | October 17, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5865 seconds.